Singapore markets open in 7 hours 38 minutes
  • Straits Times Index

    3,253.79
    -3.03 (-0.09%)
     
  • S&P 500

    4,310.66
    +13.52 (+0.31%)
     
  • Dow

    34,188.54
    +276.10 (+0.81%)
     
  • Nasdaq

    13,115.49
    -12.56 (-0.10%)
     
  • BTC-USD

    23,859.56
    -382.27 (-1.58%)
     
  • CMC Crypto 200

    567.26
    -4.66 (-0.81%)
     
  • FTSE 100

    7,536.06
    +26.91 (+0.36%)
     
  • Gold

    1,790.90
    -7.20 (-0.40%)
     
  • Crude Oil

    86.83
    -2.58 (-2.89%)
     
  • 10-Yr Bond

    2.8370
    +0.0460 (+1.65%)
     
  • Nikkei

    28,868.91
    -2.87 (-0.01%)
     
  • Hang Seng

    19,830.52
    -210.34 (-1.05%)
     
  • FTSE Bursa Malaysia

    1,518.78
    +14.77 (+0.98%)
     
  • Jakarta Composite Index

    7,133.45
    +40.18 (+0.57%)
     
  • PSE Index

    6,850.64
    +112.80 (+1.67%)
     

DiaMedica Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MINNEAPOLIS, November 17, 2021--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, President and CEO, will participate in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will also be available for one-on-one meetings.

A recording of the presentation will be available beginning on Monday, November 22, 2021, at 10:00a.m. Eastern Time. Interested parties may access the presentation in the "Investors" section of the company’s website at https://www.diamedica.com/investors/events-presentations.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Based on promising early clinical results, DiaMedica has initiated and commenced enrollment in its pivotal ReMEDy Phase 2/3 trial in the treatment of AIS and is completing enrollment in its REDUX Phase 2 trial for the treatment of certain rare and significant unmet causes of CKD. For more information visit our website at www.diamedica.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211117005053/en/

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Tim McCarthy
Managing Director, LifeSci Advisors, LLC
tim@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting